← Leaderboards
Mark J Jameson
University Of Virginia
$540,000
Attributed
$540,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $108K · FY2009–13$200K$150K$100K$50K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$540,000 · 1
By mechanism
K08$540,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Thomas P Loughran$27,014,958
- Li Li$10,636,659
- Ilya Levental$7,035,548
- Karen-Kim E Innes$1,908,057
- Gary K Owens$62,453,400
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisBaseAreaBiopsyCancer CenterCancer EtiologyCancer TypeCareerCell CycleCell LineCellsCessation Of LifeClinical EffectivenessClinical EfficacyClinical TrialsCollaborationsDevelopment PlansDominant-Negative MutationEffectivenessEgfr Protein OverexpressionElementsEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEpithelial
Grant awards (5)
Growth Factor-Induced Resistance to Targeted Therapy in Oral Cavity Cancer$108,000
K08 · FY2013 · DE · contact PI
Growth Factor-Induced Resistance to Targeted Therapy in Oral Cavity Cancer$108,000
K08 · FY2012 · DE · contact PI
Growth Factor-Induced Resistance to Targeted Therapy in Oral Cavity Cancer$108,000
K08 · FY2011 · DE · contact PI
Growth Factor-Induced Resistance to Targeted Therapy in Oral Cavity Cancer$108,000
K08 · FY2010 · DE · contact PI
Growth Factor-Induced Resistance to Targeted Therapy in Oral Cavity Cancer$108,000
K08 · FY2009 · DE · contact PI